FR2829498B1 - Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins - Google Patents

Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins

Info

Publication number: FR2829498B1
Authority: FR; France
Prior art keywords: igf; feline; retroviruses; vaccine adjuvant; especially against
Prior art date: 2001-09-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

FR0111736A

Other languages

English (en)

Other versions

FR2829498A1 (fr

Inventor

Christine Michele Pie Andreoni

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Animal Health France SAS

Boehringer Ingelheim Animal Health USA Inc

Original Assignee

Merial SAS

Merial Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-11

Filing date

2001-09-11

Publication date

2003-11-28

2001-09-11 Priority to FR0111736A priority Critical patent/FR2829498B1/fr

2001-09-11 Application filed by Merial SAS, Merial Inc filed Critical Merial SAS

2002-09-10 Priority to DE60238773T priority patent/DE60238773D1/de

2002-09-10 Priority to JP2003526958A priority patent/JP2005516587A/ja

2002-09-10 Priority to CA2459769A priority patent/CA2459769C/fr

2002-09-10 Priority to US10/238,114 priority patent/US7326417B2/en

2002-09-10 Priority to AT02755576T priority patent/ATE493146T1/de

2002-09-10 Priority to PCT/IB2002/003638 priority patent/WO2003022886A1/fr

2002-09-10 Priority to EP02755576A priority patent/EP1425305B1/fr

2003-03-14 Publication of FR2829498A1 publication Critical patent/FR2829498A1/fr

2003-11-28 Application granted granted Critical

2003-11-28 Publication of FR2829498B1 publication Critical patent/FR2829498B1/fr

2007-12-21 Priority to US11/963,085 priority patent/US20080181912A1/en

2021-09-11 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract 5
102000004218 Insulin-Like Growth Factor I Human genes 0.000 title abstract 5
241000282324 Felis Species 0.000 title abstract 3
239000012646 vaccine adjuvant Substances 0.000 title 1
229940124931 vaccine adjuvant Drugs 0.000 title 1
238000001727 in vivo Methods 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
241000282326 Felis catus Species 0.000 abstract 1
108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
230000002238 attenuated effect Effects 0.000 abstract 1
229940031567 attenuated vaccine Drugs 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
229940031551 inactivated vaccine Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
239000013612 plasmid Substances 0.000 abstract 1
229940124551 recombinant vaccine Drugs 0.000 abstract 1
229940031626 subunit vaccine Drugs 0.000 abstract 1
241001430294 unidentified retrovirus Species 0.000 abstract 1
238000002255 vaccination Methods 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Mycology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Hematology (AREA)
Diabetes (AREA)
Zoology (AREA)
Toxicology (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FR0111736A 2001-09-11 2001-09-11 Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins Expired - Lifetime FR2829498B1 (fr)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
FR0111736A FR2829498B1 (fr)	2001-09-11	2001-09-11	Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
JP2003526958A JP2005516587A (ja)	2001-09-11	2002-09-10	特にネコレトロウイスルに対する、ネコワクチンアジュバントとしてのｉｇｆ−１
CA2459769A CA2459769C (fr)	2001-09-11	2002-09-10	Igf-1 utilise comme adjuvant de vaccin felin, notamment contre les retrovirus felins
US10/238,114 US7326417B2 (en)	2001-09-11	2002-09-10	IGF-1 as feline vaccine adjuvant, in particular against feline retroviruses
DE60238773T DE60238773D1 (de)	2001-09-11	2002-09-10	Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
AT02755576T ATE493146T1 (de)	2001-09-11	2002-09-10	Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
PCT/IB2002/003638 WO2003022886A1 (fr)	2001-09-11	2002-09-10	Igf-1 utilise comme adjuvant de vaccin felin, notamment contre les retrovirus felins
EP02755576A EP1425305B1 (fr)	2001-09-11	2002-09-10	Igf-1 utilise comme adjuvant de vaccin felin, notamment contre les retrovirus felins
US11/963,085 US20080181912A1 (en)	2001-09-11	2007-12-21	Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0111736A FR2829498B1 (fr)	2001-09-11	2001-09-11	Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins

Publications (2)

Publication Number	Publication Date
FR2829498A1 FR2829498A1 (fr)	2003-03-14
FR2829498B1 true FR2829498B1 (fr)	2003-11-28

Family

ID=8867163

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR0111736A Expired - Lifetime FR2829498B1 (fr)	2001-09-11	2001-09-11	Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins

Country Status (7)

Country	Link
EP (1)	EP1425305B1 (fr)
JP (1)	JP2005516587A (fr)
AT (1)	ATE493146T1 (fr)
CA (1)	CA2459769C (fr)
DE (1)	DE60238773D1 (fr)
FR (1)	FR2829498B1 (fr)
WO (1)	WO2003022886A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7468273B2 (en)	2003-05-01	2008-12-23	Meial Limited	Canine GHRH gene, polypeptides and methods of use
JP2007522801A (ja)	2004-01-07	2007-08-16	リーブテック，インコーポレイテッド	一体のスパージャーとセンサー受け器を有する混合用袋
CA2629522A1 (fr)	2005-11-14	2007-05-18	Merial Limited	Therapie genique pour insuffisance renale
US7771995B2 (en)	2005-11-14	2010-08-10	Merial Limited	Plasmid encoding human BMP-7
US8603808B2 (en)	2008-05-08	2013-12-10	Merial Limited	Leishmania vaccine using sand fly salivary immunogen
BR112014001287B1 (pt)	2011-07-20	2020-12-08	Centre National De La Recherche Scientifique	vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
ES2711878T3 (es)	2012-03-20	2019-05-08	Merial Inc	Vacuna contra el virus del herpes equino 1 recombinante que contiene glicoproteína C mutada y usos de la misma
CN111848785B (zh) *	2020-07-10	2022-09-06	青岛博隆基因工程有限公司	猫疱疹病毒抗体序列、四肽链分子、免疫球蛋白分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1986000619A1 (fr) *	1984-07-13	1986-01-30	Chiron Corporation	Facteurs de croissance prepro i et ii analogues a l'insuline
US4963665A (en) *	1986-01-07	1990-10-16	Washington University	Human preproinsulin-like growth factor I
US5202119A (en) *	1991-06-28	1993-04-13	Genentech, Inc.	Method of stimulating immune response
AU4238493A (en) *	1992-05-08	1993-12-13	Thomas Jefferson University	IGF-1 analogs
AU1439095A (en) *	1993-12-15	1995-07-03	Thomas Jefferson University	Igf-1 analogs
GB9605124D0 (en) *	1996-03-11	1996-05-08	Royal Free Hosp School Med	Method of treating muscular disorders
FR2751223B1 (fr) *	1996-07-19	1998-12-04	Rhone Merieux	Formule de vaccin polynucleotidique felin
WO1998024922A1 (fr) *	1996-12-02	1998-06-11	Valentis, Inc.	Systeme d'expression du facteur de croissance insulinoide i (igf-i) et ses methodes d'utilisation
GB9926968D0 (en) *	1999-11-15	2000-01-12	Univ London	Treatment of neurological disorders

2001
- 2001-09-11 FR FR0111736A patent/FR2829498B1/fr not_active Expired - Lifetime
2002
- 2002-09-10 JP JP2003526958A patent/JP2005516587A/ja active Pending
- 2002-09-10 EP EP02755576A patent/EP1425305B1/fr not_active Expired - Lifetime
- 2002-09-10 CA CA2459769A patent/CA2459769C/fr not_active Expired - Lifetime
- 2002-09-10 AT AT02755576T patent/ATE493146T1/de not_active IP Right Cessation
- 2002-09-10 DE DE60238773T patent/DE60238773D1/de not_active Expired - Lifetime
- 2002-09-10 WO PCT/IB2002/003638 patent/WO2003022886A1/fr not_active Ceased

Also Published As

Publication number	Publication date
EP1425305B1 (fr)	2010-12-29
CA2459769C (fr)	2013-05-28
WO2003022886A1 (fr)	2003-03-20
EP1425305A1 (fr)	2004-06-09
JP2005516587A (ja)	2005-06-09
ATE493146T1 (de)	2011-01-15
FR2829498A1 (fr)	2003-03-14
CA2459769A1 (fr)	2003-03-20
DE60238773D1 (de)	2011-02-10

Legal Events

Date	Code	Title	Description
2015-09-17	PLFP	Fee payment	Year of fee payment: 15
2016-09-26	PLFP	Fee payment	Year of fee payment: 16
2017-09-25	PLFP	Fee payment	Year of fee payment: 17
2018-09-25	PLFP	Fee payment	Year of fee payment: 18
2019-09-25	PLFP	Fee payment	Year of fee payment: 19
2020-09-25	PLFP	Fee payment	Year of fee payment: 20

Publication	Publication Date	Title
ES2753854T3 (es)	2020-04-14	Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de los mismos
ES2638577T3 (es)	2017-10-23	Vectores adenovirales que codifican un patógeno o antígeno tumoral
CY1110359T1 (el)	2015-04-29	Εμβολια με βαση σιρκοϊους χοιρων
NO992369D0 (no)	1999-05-14	Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
ATE526411T1 (de)	2011-10-15	Avirulente, immunogene flavivirus-chimäre
PT1487485E (pt)	2011-03-11	Adjuvantes de imidazoquinolina para vacinas de adn
BR0206823A (pt)	2004-02-25	Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo
WO2004050856A3 (fr)	2005-03-24	Vaccins a adn polyvalents contre la glycoproteine du vih-1 primaire et procedes de vaccination
BR9814204A (pt)	2000-10-03	"obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
WO2008151633A3 (fr)	2009-04-23	Vecteurs pour un vaccin contre le vih-1
EP2290091A3 (fr)	2011-05-04	Virus de la rougeole recombinants exprimant des epitopes d' antigenes de virus à ARN et utilisation des virus recombinants pour la preparation de vaccins
WO2005081716A3 (fr)	2009-04-02	Vaccins adn ciblant des antigenes du coronavirus du syndrome respiratoire aigu severe (sars-cov)
WO2002022686A3 (fr)	2003-03-13	Proteines de fusion defensine-antigene
Kadkhodayan et al.	2017	Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model
ATE493146T1 (de)	2011-01-15	Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
ES2439954T3 (es)	2014-01-27	Vectores víricos recombinantes para la prevención y la protección contra la infección por alfavirus
AU6683400A (en)	2001-01-30	Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
US20200362316A1 (en)	2020-11-19	Vesicular stomatitis vectors encoding crimean-congo hemorrhagic fever antigen
Zeng et al.	2008	Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice
Wang et al.	2005	Immunogenicity of a bovine viral diarrhea virus E2–C3d fusion protein containing a bovine homolog of C3d
DK177298B1 (en)	2012-10-15	Nucleic Acid and Amino Acid Sequences of Infectious Salmon Anaemia Virus and their Use as Vaccines
WO2021150713A3 (fr)	2021-10-07	Épitopes immunogènes humains de rétrovirus endogènes humains (herv) h, k et e
KR101937792B1 (ko)	2019-01-14	신규한 재조합 항원 단백질을 포함하는 구제역 백신 조성물
WO2007143606A3 (fr)	2008-11-13	Séquences consensus, antigènes et transgènes du clade a du vih-1
KR20240109612A (ko)	2024-07-11	세포 막에서 항원을 발현시키기 위한 조성물 및 방법